- The FDA has authorized COVID-19 shots from Moderna Inc (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE)/ BioNTech SE (NASDAQ:BNTX) targeting the original coronavirus and Omicron sub-variants for use in children as young as six months of age.
- The amended authorization allows the use of Moderna’s bivalent shot as a booster in children six months through 5 years of age, two months after their initial vaccination.
- Pfizer/BioNTech’s updated shot can now be given as a third dose to those aged six months through 4 years who have not completed their primary vaccination series or are yet to receive the third dose.
- Related: Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims.
- The agency said that children who have completed their initial three-dose vaccination with Pfizer’s original shot are not yet eligible to receive the bivalent booster.
- FDA said that data supporting Pfizer/BioNtech’s bivalent shot as a booster for children aged six months – 4 years is expected in January.
- Price Action: PFE stock is up 2.23% at $51.36, BNTX shares are up 3.78% at $168.78, and MRNA shares are up 1.73% at $182.09 on the last check Thursday.
Keybanc Maintains Overweight on TechTarget, Lowers Price Target to $60
Keybanc analyst Justin Patterson maintains TechTarget (NASDAQ:TTGT) with a Overweight and lowers the price target from $70 to $60.
